Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients

Antiviral Therapy

Volumn 19, Issue 5, 2014, Pages 455-461

  Grammatikos, Georgios ^a   Jabara, Cassandra B ^b   Ahmad, Monazza Q ^a   Herrmann, Eva ^c   Zeuzem, Stefan ^a   Welsch, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE; NONSTRUCTURAL PROTEIN 3; PROTEINASE; PROTEINASE INHIBITOR; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; NUCLEIC ACID BASE SUBSTITUTION; OUTCOME ASSESSMENT; PHYLOGENY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TREATMENT RESPONSE; VIRAL GENETICS; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENE LINKAGE DISEQUILIBRIUM; GENETICS; HEPACIVIRUS; HUMAN; MUTATION; PROTEIN CONFORMATION; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C; HUMANS; LINKAGE DISEQUILIBRIUM; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84924340920     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2734     Document Type: Article

References (34)

1. Neal KR, Ramsay S, Thomson B.J., et al Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56:1098-1104.
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13:2436-2441.
3. Hézode C., Forestier N, Dusheiko G., et al Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
4. Kwo PY, Lawitz EJ, McCone J, et al Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 2010; 376:705-716.
5. Neumann AU, Lam NP, Dahari H, et al Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferonalpha therapy. Science 1998; 282:103-107.
6. Rong L, Dahari H, Ribeiro R.M., et al Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra32.
7. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138:447-462.
8. Raney KD, Sharma SD, Moustafa I.M., et al Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem 2010; 285:22725-22731.
9. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat 1999; 6:165-181.
10. Ferreon JC, Ferreon AC, Li K, et al Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol Chem 2005; 280:20483-20492.
11. Grakoui A, Wychowski C, Lin C., et al Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67:1385-1395.
12. Li K, Foy E, Ferreon J.C., et al Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102:2992-2997.
13. Ma Y, Yates J, Liang Y., et al NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J Virol 2008; 82:7624-7639.
14. Beran RK, Pyle AM Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J Biol Chem 2008; 283:29929-29937.
15. Rajagopal V, Gurjar M, Levin M.K., et al The protease domain increases the translocation stepping efficiency of the hepatitis C virus NS3-4A helicase. J Biol Chem 2010; 285:17821-17832.
16. Morgenstern KA, Landro JA, Hsiao K, et al Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells. J Virol 1997; 71:3767-3775.
17. Pan RY, Hung TM, Kou Y.H., et al In trans interaction of hepatitis C virus helicase domains mediates protease activity critical for internal NS3 cleavage and cell transformation. FEBS Lett 2010; 584:482-486.
18. Yao N, Reichert P, Taremi S.S., et al Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999; 7:1353-1363.
19. Saalau-Bethell S.M., Woodhead AJ, Chessari G, et al Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 2012; 8:920-925.
20. Xue W, Wang M, Jin X., et al Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis. Mol Biosyst 2012; 8:2753-2765.
21. Pawlotsky JM, Germanidis G, Frainais P.O., et al Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 1999; 73:6490-6499.
22. Yao N, Reichert P, Taremi S.S., et al Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999; 7:1353-1363.
23. Berman HM, Battistuz T, Bhat T.N., et al The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 2002; 58:899-907.
24. Combet C, Garnier N, Charavay C., et al euHCVdb: the European hepatitis C virus database. Nucleic Acids Res 2007; 35:D363-D366.
25. Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 1993; 10:512-526.
26. Susser S, Welsch C, Wang Y., et al Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50:1709-1718.
27. Bacon BR, Gordon SC, Lawitz E, et al Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
28. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
29. Kuntzen T, Timm J, Berical A., et al Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-1778.
30. Coutsinos D, Invernizzi C F, Moisi D, et al A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS ONE 2011; 6:e20208.
31. Powdrill MH, Tchesnokov E P, Kozak RA, et al Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A 2011; 108:20509-20513.
32. Shimakami T, Welsch C, Yamane D., et al Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 2011; 140:667-675.
33. Welsch C, Schweizer S, Shimakami T., et al Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease. Antimicrob Agents Chemother 2012; 56:1907-1915.
34. Welsch C, Shimakami T, Hartmann C., et al Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease. Gastroenterology 2012; 142:654-663.